World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
60
Citations
12075
World Ranking
3343
National Ranking
139

Gail V. Matthews publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Gail V. Matthews sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 292 publications — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Gail V. Matthews D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Gail V. Matthews sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 60 D-Index — 33rd percentile

33% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Gail V. Matthews is affiliated with the University of New South Wales in Australia. Their research output primarily focuses on the field of Medicine, with notable contributions in Epidemiology, Infectious Diseases, Hepatology, Neurology, and Immunology.

Their work extensively covers several main research topics, including:

  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Liver Disease Diagnosis and Treatment
  • SARS-CoV-2 and COVID-19 Research
  • HIV, Drug Use, Sexual Risk
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19

Gail V. Matthews has published frequently in the following venues:

  • Journal of Hepatology
  • Clinical Infectious Diseases
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Viral Hepatitis
  • Open Forum Infectious Diseases

Their recent papers include:

  • Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection, 2022, Nature Immunology
  • SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, 2022, EBioMedicine
  • SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants, 2021, PLoS Medicine
  • Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis, 2020, The Lancet. Gastroenterology & hepatology
  • Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial, 2022, The Lancet Respiratory Medicine

Frequent collaborators in their research include:

  • Gregory J. Dore
  • Marianne Martinello
  • Behzad Hajarizadeh
  • Jason Grebely
  • Anthony D. Kelleher

Best Publications

  • Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

    Paul Bastard;Adrian Gervais;Adrian Gervais;Tom Le Voyer;Tom Le Voyer;Jérémie Rosain;Jérémie Rosain

  • Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

    Gillian L. Dean;Simon G. Edwards;Natalie J. Ives;Gail Matthews

  • Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men

    Thijis van de Laar;Oliver Pybus;Sylvia Bruisten;David Brown

  • Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial

    Jürgen K. Rockstroh;Mark Nelson;Christine Katlama;Jay Lalezari

  • Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection.

    Thijs J W van de Laar;Gail V Matthews;Maria Prins;Mark Danta

  • Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

    Jason Grebely;Olav Dalgard;Brian Conway;Evan B Cunningham

  • Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy.

    Gail V. Matthews;Mark Bower;Sundhiya Mandalia;Tom Powles

  • Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.

    Jason Grebely;Kathy Petoumenos;Margaret Hellard;Margaret Hellard;Gail V. Matthews;Gail V. Matthews

  • An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.

    M Nelson;S Portsmouth;J Stebbing;M Atkins

  • Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

    Gail V Matthews;Angeline Bartholomeusz;Stephen Locarnini;Anna Ayres

  • Acute hepatitis C in HIV-infected individuals : recommendations from the European AIDS Treatment Network (NEAT) consensus conference The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel

    Matthieu Albert;Jose Benito;Sanjay Bhagani;Christoph Boesecke

  • IL28B, HLA-C and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a european cohort: A cross-sectional study

    Vijayaprakash Suppiah;Silvana Gaudieri;Nicola J. Armstrong;Kate S. O'Connor

  • Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease

    Mohammed Eslam;Ahmed M Hashem;Reynold Leung;Manuel Romero-Gomez

  • Sexually transmitted hepatitis C infection: the new epidemic in MSM?

    Daniel Bradshaw;Gail Matthews;Mark Danta

  • A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

    Gail V. Matthews;Anchalee Avihingsanon;Sharon R. Lewin;Sharon R. Lewin;Janaki Amin

  • Effective treatment of injecting drug users with recently acquired Hepatitis C virus infection

    Gregory J. Dore;Gregory J. Dore;Margaret Hellard;Margaret Hellard;Gail V. Matthews;Gail V. Matthews;Jason Grebely

  • Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

    Gail V. Matthews;Caroline. A. Sabin;Sundhiya Mandalia;Fiona Lampe

  • SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

    Unknown

  • SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.

    Fiona Tea;Alberto Ospina Stella;Anupriya Aggarwal;David Ross Darley;David Ross Darley

  • Characteristics and Treatment Outcomes among HIV-Infected Individuals in the Australian Trial in Acute Hepatitis C

    G. V. Matthews;M. Hellard;P. Haber;B. Yeung

  • Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users

    Jason Grebely;Gail V. Matthews;Gail V. Matthews;Margaret Hellard;Margaret Hellard;David Shaw

  • Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection

    Chansavath Phetsouphanh;David Darley;Anette Howe;C. Mee Ling Munier

Frequent Co-Authors

Gregory J. Dore
Gregory J. Dore University of New South Wales
Margaret Hellard
Margaret Hellard Burnet Institute
Jason Grebely
Jason Grebely University of New South Wales
Sharon R. Lewin
Sharon R. Lewin University of Melbourne
Andrew R. Lloyd
Andrew R. Lloyd University of New South Wales
John M. Kaldor
John M. Kaldor University of New South Wales
Janaki Amin
Janaki Amin Macquarie University
William D. Rawlinson
William D. Rawlinson University of New South Wales
Kiat Ruxrungtham
Kiat Ruxrungtham Chulalongkorn University
Alexander J. Thompson
Alexander J. Thompson Ascension Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related online degrees such as nurse practitioner programs can open diverse career paths in healthcare. Many prospective students look for easy nurse practitioner programs to get into as a way to efficiently advance their education and enter the workforce faster.

Specializing further, programs like the best pmhnp programs offer strong clinical placements, which are crucial for hands-on experience in psychiatric mental health nursing. These programs align well with individuals who want to combine immunology knowledge with mental health expertise.

Budget-conscious students often seek out the cheapest psychiatric nurse practitioner programs, which still provide quality education without the financial burden. Balancing cost with program quality is a key consideration in selecting the right educational pathway.

Finally, understanding compensation trends is essential. The dnp salary transparency resource offers insight into salary expectations by location, helping graduates make informed decisions about where to pursue their careers post-degree.

Best Scientists Citing Gail V. Matthews

Trending Scientists

Recently Published Articles